Emergent Biosolutions (EBS) Stock Price, Quote & News

Company Profile

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax va...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 240 631 3200

Website: www.emergentbiosolutions.com

Address:

300 Professional Drive, Gaithersburg, United States

KnuckleSandwich Feb. 3 at 5:28 AM

$EBS NRG8 is a paper tiger 🐯

0 · Reply

ComradeKomisar Feb. 3 at 3:32 AM

$EBS Pretty good.

1 · Reply

ImmxBeliever Feb. 2 at 10:58 PM

$EBS This gOOd or bad 🤣🤣🤣

1 · Reply

ComradeKomisar Feb. 2 at 10:46 PM

$EBS mid February at the latest. There be catalysts, cataclysms, catamites like @ImmxBeliever

1 · Reply

alwayzwong Feb. 2 at 10:28 PM

$EBS my guess is that volume will be anemic until earnings…

1 · Reply

ComradeKomisar Feb. 2 at 9:50 PM

$EBS Tomorrow is the day. 2 years of autopilot should end for ASPR/BARDA/SNS

1 · Reply

alwayzwong Feb. 2 at 9:45 PM

$EBS looks like we ended the day with a bullish engulfing candle on the daily.

0 · Reply

Moon22 Feb. 2 at 9:08 PM

$EBS lowest volume since shortened session Christmas eve 🫤

0 · Reply

Kazoonova Feb. 2 at 9:03 PM

$EBS Decent recovery, but volume is still garbage.

0 · Reply

ImmxBeliever Feb. 2 at 8:51 PM

$EBS back below 50 DMA

1 · Reply

NY Attorney General Sues Former Emergent BioSolutions CEO for Insider Trading

Jan 14, 2026, 11:55 PM EST - 19 days ago

Emergent BioSolutions Inc. (EBS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 7:30 AM EST - 21 days ago

Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation

Jan 8, 2026, 4:30 PM EST - 25 days ago

Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026

Jan 8, 2026, 8:00 AM EST - 25 days ago

Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa

Jan 7, 2026, 7:59 AM EST - 26 days ago

Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 12, 2025, 8:30 AM EST - 7 weeks ago

Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site

Nov 18, 2025, 8:00 AM EST - 2 months ago

Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access

Nov 12, 2025, 4:01 PM EST - 2 months ago

Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors

Nov 6, 2025, 11:00 PM EST - 3 months ago

Emergent BioSolutions: Solid Q3, Expecting Better Days To Come

Oct 29, 2025, 8:56 PM EDT - 3 months ago

Emergent BioSolutions Inc. (EBS) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 4:15 PM EDT - 3 months ago

Emergent BioSolutions Reports Third Quarter 2025 Financial Results

Oct 28, 2025, 8:00 AM EDT - 3 months ago

Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness

Oct 8, 2025, 7:45 AM EDT - 4 months ago

Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025

Sep 24, 2025, 4:05 PM EDT - 4 months ago

Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone

Sep 19, 2025, 8:34 AM EDT - 4 months ago

Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner

Sep 15, 2025, 8:35 AM EDT - 5 months ago

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

Sep 9, 2025, 7:30 AM EDT - 5 months ago

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

Sep 2, 2025, 7:40 AM EDT - 5 months ago

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

Aug 29, 2025, 8:05 AM EDT - 5 months ago

Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day

Aug 27, 2025, 8:01 AM EDT - 5 months ago

Emergent BioSolutions to Participate in Upcoming Investor Conferences

Aug 21, 2025, 8:45 AM EDT - 5 months ago

Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™

Aug 12, 2025, 12:46 PM EDT - 6 months ago

Emergent BioSolutions: Q2 Results Could Spark A Strong 2025 Rally

Aug 7, 2025, 7:31 PM EDT - 6 months ago

Emergent BioSolutions Inc. (EBS) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:15 PM EDT - 6 months ago

Emergent BioSolutions Reports Second Quarter 2025 Financial Results

Jul 28, 2025, 8:50 AM EDT - 6 months ago

Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives

Jul 28, 2025, 8:50 AM EDT - 6 months ago

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox

Jul 15, 2025, 7:30 AM EDT - 7 months ago

Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 8, 2025, 4:45 PM EDT - 7 months ago

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts

Jul 2, 2025, 4:05 PM EDT - 7 months ago

Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate

Jun 23, 2025, 8:05 AM EDT - 8 months ago

Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply

Jun 20, 2025, 2:25 PM EDT - 8 months ago

Emergent BioSolutions: Strategic Turnaround Proving Tricky, But I'm Still Hopeful

Jun 20, 2025, 8:13 AM EDT - 8 months ago

Emergent BioSolutions Announces Addition to Russell 3000® Index

Jun 5, 2025, 7:00 AM EDT - 8 months ago

Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies

May 7, 2025, 10:01 PM EDT - 9 months ago

Emergent BioSolutions Inc. (EBS) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 9 months ago

Emergent BioSolutions Reports First Quarter 2025 Financial Results

May 1, 2025, 5:07 PM EDT - 9 months ago

Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health

Apr 22, 2025, 8:00 AM EDT - 10 months ago

Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025

Mar 31, 2025, 8:00 AM EDT - 11 months ago

Emergent BioSolutions Announces Stock Repurchase Program

Mar 20, 2025, 4:30 PM EDT - 11 months ago

Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

Mar 20, 2025, 8:06 AM EDT - 11 months ago

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

Mar 19, 2025, 4:30 PM EDT - 11 months ago

Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International

Mar 18, 2025, 8:00 AM EDT - 11 months ago

Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products

Mar 13, 2025, 8:29 AM EDT - 11 months ago

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs

Mar 12, 2025, 8:00 AM EDT - 11 months ago

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

Mar 10, 2025, 9:14 AM EDT - 11 months ago

Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International

Mar 3, 2025, 7:58 PM EST - 1 year ago

Emergent BioSolutions Inc. (EBS) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 4:23 PM EST - 1 year ago

Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 18, 2025, 8:55 AM EST - 1 year ago

Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Feb 7, 2025, 8:06 AM EST - 1 year ago

Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans

KnuckleSandwich Feb. 3 at 5:28 AM

$EBS NRG8 is a paper tiger 🐯

0 · Reply

ComradeKomisar Feb. 3 at 3:32 AM

$EBS Pretty good.

1 · Reply

ImmxBeliever Feb. 2 at 10:58 PM

$EBS This gOOd or bad 🤣🤣🤣

1 · Reply

ComradeKomisar Feb. 2 at 10:46 PM

$EBS mid February at the latest. There be catalysts, cataclysms, catamites like @ImmxBeliever

1 · Reply

alwayzwong Feb. 2 at 10:28 PM

$EBS my guess is that volume will be anemic until earnings…

1 · Reply

ComradeKomisar Feb. 2 at 9:50 PM

$EBS Tomorrow is the day. 2 years of autopilot should end for ASPR/BARDA/SNS

1 · Reply

alwayzwong Feb. 2 at 9:45 PM

$EBS looks like we ended the day with a bullish engulfing candle on the daily.

0 · Reply

Moon22 Feb. 2 at 9:08 PM

$EBS lowest volume since shortened session Christmas eve 🫤

0 · Reply

Kazoonova Feb. 2 at 9:03 PM

$EBS Decent recovery, but volume is still garbage.

0 · Reply

ImmxBeliever Feb. 2 at 8:51 PM

$EBS back below 50 DMA

1 · Reply

WinstonSmith33 Feb. 2 at 8:49 PM

$EBS Bavarian Nordic bought back literally 0.8% of all outstanding shares in 3 WEEKS. They are able to report the situation in: THE NEXT DAY. We have to wait for THE SAME information: 5 months (Q4 report). PS. Any comment from Poor Rich? https://uk.finance.yahoo.com/news/bavarian-nordic-transactions-connection-share-075400927.html

0 · Reply

ComradeKomisar Feb. 2 at 8:19 PM

$EBS Sharting into shiddy liquidity is a not so bold move by low IQ individuals.

1 · Reply

ComradeKomisar Feb. 2 at 6:58 PM

$EBS Back to 50DMA

0 · Reply

GrantDiaz Feb. 2 at 6:53 PM

$EBS Surprise, Surprise... @NRG8 blocked me. Good riddance you total fake!

4 · Reply

alwayzwong Feb. 2 at 5:49 PM

$EBS don’t know what’s @ImmxBeliever final goal with all this chit posting. It’s childish at best and stupid at worst.

1 · Reply

ComradeKomisar Feb. 2 at 5:20 PM

$EBS Nevertheless, 'they' desisted.

1 · Reply

alwayzwong Feb. 2 at 4:38 PM

$EBS ER is a few weeks away..

1 · Reply

ComradeKomisar Feb. 2 at 4:33 PM

$EBS No good deed goes unpunished. Without Cassidy's vote, RFK Jr would not have passed confirmation in Senate.

0 · Reply

billywilliamz Feb. 2 at 4:07 PM

$EBS buyout imminent

0 · Reply

SignoreRossi Feb. 2 at 2:46 PM

$EBS Key risk remains communication quality. Management provides limited forward guidance. Until transparency and proactive investor communication materially improve, valuation pressure is understandable.

1 · Reply

ImmxBeliever Feb. 2 at 3:41 AM

$EBS Futures look down Biggly I love that all the Orange Gods worshippers will lose their trailers and pickup trucks 🤣🤣🤣

1 · Reply

Martylevitt Feb. 1 at 3:13 PM

$EBS https://www.emergentbiosolutions.com/press/news-release-details-cepi-awards-25-million-contract-profectus-biosciences-and-0/

4 · Reply

Market Cap	595.58M
Revenue (ttm)	1.04B
Net Income (ttm)	-190.60M
EPS (ttm)	N/A
PE Ratio	6.01
Forward PE	N/A
Profit Margin	-18.26%
Debt to Equity Ratio	1.14

Volume	485,500
Avg Vol	869,238
Day's Range	N/A - N/A
Shares Out	52.52M
Stochastic %K	41%
Beta	2.30
Analysts	Strong Sell
Price Target	$13.50